Category: Ascendis
-
Ascendis stock falls as FDA delays TransCon PTH review
•
Grandparents Editorial/iStock via Getty Images Ascendis Pharma (ASND) announced Tuesday that the U.S. Food and Drug Administration (FDA) has postponed the timeline for completing its review of the company’s experimental hypoparathyroidism treatment, TransCon PTH. The Food and Drug Administration considered the information provided by the company Regarding the New Drug…